摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[4-(1,4-dioxa-spiro[4.5]dec-8-yl)-phenyl]-acetic acid ethyl ester | 1252615-91-0

中文名称
——
中文别名
——
英文名称
[4-(1,4-dioxa-spiro[4.5]dec-8-yl)-phenyl]-acetic acid ethyl ester
英文别名
Ethyl 2-[4-(1,4-dioxaspiro[4.5]decan-8-yl)phenyl]acetate
[4-(1,4-dioxa-spiro[4.5]dec-8-yl)-phenyl]-acetic acid ethyl ester化学式
CAS
1252615-91-0
化学式
C18H24O4
mdl
——
分子量
304.386
InChiKey
HCBMFLMRSPEBRA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    22
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.61
  • 拓扑面积:
    44.8
  • 氢给体数:
    0
  • 氢受体数:
    4

文献信息

  • 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2
    申请人:Zhang Xuqing
    公开号:US20100267689A1
    公开(公告)日:2010-10-21
    The present invention comprises compounds of Formula (I): wherein: X, R 1 , R 2 , R 3 , and R 4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).
    本发明涵盖了以下式(I)的化合物: 其中:X,R1,R2,R3和R4如规范中所定义。该发明还涵盖了一种预防、治疗或改善综合征、疾病或疾病的方法,其中所述综合征、疾病或疾病是II型糖尿病、肥胖和哮喘。该发明还涵盖了通过给哺乳动物施用至少一种式(I)化合物的治疗有效量来抑制CCR2活性的方法。
  • US8513229B2
    申请人:——
    公开号:US8513229B2
    公开(公告)日:2013-08-20
  • [EN] 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2<br/>[FR] ANTAGONISTES DE CCR2 A BASE DE 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2010121046A1
    公开(公告)日:2010-10-21
    The present invention comprises compounds of Formula (I) wherein: X, R1, R2, R3, and R4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).
查看更多